126 related articles for article (PubMed ID: 33303601)
1. China's vaccine gambit.
Cohen J
Science; 2020 Dec; 370(6522):1263-1267. PubMed ID: 33303601
[No Abstract] [Full Text] [Related]
2. China's COVID vaccines are going global - but questions remain.
Mallapaty S
Nature; 2021 May; 593(7858):178-179. PubMed ID: 33948031
[No Abstract] [Full Text] [Related]
3. Unfolding the Determinants of COVID-19 Vaccine Acceptance in China.
Yin F; Wu Z; Xia X; Ji M; Wang Y; Hu Z
J Med Internet Res; 2021 Jan; 23(1):e26089. PubMed ID: 33400682
[TBL] [Abstract][Full Text] [Related]
4. A review of COVID-19 vaccines in development: 6 months into the pandemic.
Sanicas M; Sanicas M; Diop D; Montomoli E
Pan Afr Med J; 2020; 37():124. PubMed ID: 33425157
[TBL] [Abstract][Full Text] [Related]
5. Inside China's response to COVID.
Murphy F
Nature; 2020 Dec; 588(7836):S49-S51. PubMed ID: 33268870
[No Abstract] [Full Text] [Related]
6. What China's speedy COVID vaccine deployment means for the pandemic.
Cyranoski D
Nature; 2020 Oct; 586(7829):343-344. PubMed ID: 33033397
[No Abstract] [Full Text] [Related]
7. COVID-19 human challenge studies in the UK.
Kirby T
Lancet Respir Med; 2020 Dec; 8(12):e96. PubMed ID: 33137284
[No Abstract] [Full Text] [Related]
8. First vaccine may stymie hunt for better ones.
Cohen J
Science; 2020 Oct; 370(6515):389-390. PubMed ID: 33093087
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.
Iserson KV
Camb Q Healthc Ethics; 2021 Jan; 30(1):59-68. PubMed ID: 32498742
[TBL] [Abstract][Full Text] [Related]
10. Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.
Lee GM; Romero JR; Bell BP
JAMA; 2020 Nov; 324(19):1937-1938. PubMed ID: 33064152
[No Abstract] [Full Text] [Related]
11. Status of vaccine development for COVID-19.
Mendes A
Br J Community Nurs; 2020 Dec; 25(12):620-621. PubMed ID: 33275511
[No Abstract] [Full Text] [Related]
12. An update on the global vaccine development for coronavirus.
Rab S; Afjal ; Javaid M; Haleem A; Vaishya R
Diabetes Metab Syndr; 2020; 14(6):2053-2055. PubMed ID: 33113472
[No Abstract] [Full Text] [Related]
13. The story behind COVID-19 vaccines.
Fauci AS
Science; 2021 Apr; 372(6538):109. PubMed ID: 33833099
[No Abstract] [Full Text] [Related]
14. Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development.
Kahn JP; Henry LM; Mastroianni AC; Chen WH; Macklin R
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28538-28542. PubMed ID: 33122444
[No Abstract] [Full Text] [Related]
15. Shots of hope.
Cohen J
Science; 2020 Dec; 370(6523):1392-1394. PubMed ID: 33335045
[No Abstract] [Full Text] [Related]
16. Ethics and Professionalism on the Frontline: Controlled Human Infection Trials in COVID-19 Vaccine Development: Ethical Considerations.
Lucido C
S D Med; 2020 Oct; 73(10):490-492. PubMed ID: 33264530
[No Abstract] [Full Text] [Related]
17. Access considerations for a COVID-19 vaccine for South Africa.
Bangalee V; Suleman F
S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
[TBL] [Abstract][Full Text] [Related]
18. Avoiding exploitation in multinational covid-19 vaccine trials.
Iyer AA; Millum J; Grady C; Wendler D
BMJ; 2021 Mar; 372():n541. PubMed ID: 33664082
[No Abstract] [Full Text] [Related]
19. How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
Shakir S; Lane S; Davies M
Drug Saf; 2021 Jan; 44(1):1-5. PubMed ID: 33219926
[No Abstract] [Full Text] [Related]
20. Public preference for COVID-19 vaccines in China: A discrete choice experiment.
Dong D; Xu RH; Wong EL; Hung CT; Feng D; Feng Z; Yeoh EK; Wong SY
Health Expect; 2020 Dec; 23(6):1543-1578. PubMed ID: 33022806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
